Acutaas Chemicals has shifted its business toward high-margin contract manufacturing, significantly boosting its profit margins to 35.9% in FY26. While the company is aggressively expanding into battery and semiconductor chemicals, these segments are still in early stages. The stock now trades at 76 times its earnings, reflecting high market expectations for future growth execution.
What Happened
Acutaas Chemicals has successfully transformed its business model by moving toward Contract Development and Manufacturing Organisation (CDMO) operations. This strategic change focuses on developing and manufacturing complex chemical products for global innovators, moving away from a primary focus on generic products. While the company still earns 87.7% of its revenue from Active Pharmaceutical Ingredients (API), its work with global pharmaceutical companies under the CDMO model has become a primary driver of its improved financial profile.
Financial Transformation And Margins
The shift to the CDMO model has led to a major change in the company's financial performance. In FY26, the company reported revenue of Rs 1,339 crore, up from Rs 718 crore in FY24. More importantly, profit margins have seen a sharp increase. The EBITDA margin, which measures operational efficiency, widened to 35.9% in FY26 compared to 17.9% in FY24. The net profit after tax reached Rs 356.4 crore, a significant jump from Rs 80.8 crore two years prior.
These improvements are also reflected in return ratios, with the Return on Capital Employed (ROCE) rising to 39.3%. The company attributes this to a strategy of backward integration for over 90% of its products, which helps manage input costs, and a long-term supply agreement with global major Bayer, which is expected to see a 50% surge in demand by 2026.
Why Investors Are Pricing It At 76x
The stock currently trades at a valuation of approximately 76 times its FY26 earnings. In stock market terms, a high Price-to-Earnings (P/E) ratio typically means that investors are willing to pay a premium today because they expect strong, rapid earnings growth in the future. The market is effectively betting that Acutaas can continue to scale its CDMO business and successfully commercialize its new product pipeline. Because this valuation is high compared to many traditional chemical firms, the company faces the challenge of justifying this price tag through consistent delivery on its growth promises.
Growth Bets In Batteries And Chips
Beyond pharmaceuticals, Acutaas is investing heavily in semiconductor and battery chemicals. The semiconductor segment, which generated Rs 15.7 crore in FY26, involves the production of photoresist chemicals. The company has invested Rs 200 crore in a joint venture, Indichem Inc., to build a facility in South Korea.
Similarly, the company has begun commercializing electrolyte additives for lithium-ion and sodium-ion batteries, with a capacity of 2,000 metric tonnes per annum. While these segments are expanding, they are currently in the early stages of commercial production and have not yet contributed materially to the company's overall earnings. The success of these ventures will depend on the company's ability to compete in global markets.
What To Watch Next
Investors are likely to monitor several key factors as the company executes its plans. First, the success of the four new CDMO products currently awaiting regulatory approval will be important for hitting management’s revenue targets. Second, as the semiconductor and battery chemical segments grow, the market will look for evidence that these divisions can become meaningful contributors to the bottom line. Finally, given the high valuation, any delay in project execution, regulatory hurdles, or a slowdown in global demand for its API products could influence market sentiment.